Press Release


CanSino Receives Another Strong Boost
Oct 09, 2024 19:29 JST
CanSino Biologics Inc. ("CanSinoBIO" or "the Company") has announced a milestone in its fight against polio.
More info..

CanSinoBIO Reports Outstanding H1 2024 Performance
Aug 29, 2024 22:23 JST
CanSino Biologics Inc. (CanSinoBIO) today disclosed its performance report for the first half of 2024, with revenue reaching 303 million yuan, while losses were substantially reduced.
More info..

CanSinoBIO CSO Shares Latest Results of the Company's Globally Innovative Pneumococcal Vaccine
Apr 26, 2024 15:36 JST
On April 20, the 2024 National Vaccines and Health Conference organized by the Chinese Preventive Medicine Association (CPMA) and the Chinese Center for Disease Control and Prevention (China CDC) took place in the Xiong'an New Area of Hebei Province.
More info..

The Commercialization of Asia's First Meningococcal Conjugate Vaccine From CanSinoBIO Represents a Significant Breakthrough
Mar 27, 2024 21:46 JST
In 2023, CanSinoBIO's meningococcal conjugate vaccine achieved revenue approximately RMB561.72 million, representing a year-on-year increase of approximately 266.39% compared to last year. The growth trend is evident.
More info..

Latest Release


More Latest Release >>